west china medical publishers
Author
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Author "ZHANG Yulong" 3 results
  • Safety and Effectiveness of Nicorandil for Preventing No-Reflow: A Systematic Review

    Objective To evaluate the clinical efficacy and safety of nicorandil injection for preventing slow-flow/ no-reflow phenomenon after coronary stent implantation. Methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 2, 2009), PubMed, MEDLINE, EMbase, CBM, CNKI, VIP, Wanfang database, etc. from their inception to April 2009. Some relevant journals were handsearched as well. Two reviewers independently evaluated the quality of included studies and extracted the data. Meta-analysis was performed by RevMan 5.0 software. Results Seven randomized controlled trials (RCTs) involving 630 patients were included. The results of meta-analyses showed that intracoronary and intravenous nicorandil could reduce the incidence of no-reflow/ low-flow, reduce Corrected TIMI Frame Count (CTFC), and improve left ventricular ejection fraction (LVEF). Intravenous nicorandil could reduce the incidence of ventricular tachycardia/ventricular fibrillation (VT/VF), pericardial effusion, heart failure, but couldn’t reduce the incidence of death and recurrent myocardial infarction (MI) death. Conclusion Evidence shows that intracoronary nicorandil could prevent no-reflow/ slow-flow, reduce CTFC, improve LVEF, and reduce adverse reaction in patients after coronary stent implantation. However, there is a moderate possibility of selection bias, performance bias and publication bias in this review because of the small number of the included studies, which weakens the strength of the evidence of our results. More large sample size, high-quality RCTs are needed.

    Release date:2016-09-07 11:23 Export PDF Favorites Scan
  • Effectiveness of Problem-Based Learning to Improve Clinical Practice Skills for Clinical Students after Graduation: A Systematic Review

    Objective To assess the effect of problem-based learning (PBL) to improve clinical practice skills for clinical students after graduation. Methods Computer retrieval was conducted to search for controlled studies comparing PBL with non-PBL. The quality of the included studies was critically evaluated and data were analyzed. Results A total of 16 articles were included. The results showed that in integrated capabilities, PBL teaching was superior to traditional teaching methods. Whether in self-evaluation or objective evaluation, in terms of legal and ethical aspects of health care, research and presentation skills and ability to solve problem, PBL teaching was superior to non-PBL-learning methods. But in other aspects, it was yet controversial whether PBL-learning was better than non-PBL-learning. Conclusion Problem-based learning could improve clinical practice skills for clinical students after graduation. However, most trials included are of low quality, so large-scale randomized controlled trials of higher quality are needed to confirm this.

    Release date:2016-09-07 11:23 Export PDF Favorites Scan
  • Effectiveness and Safety of Cilostazol for Restenosis after Percutaneous Coronary Intervention: A Meta-Analysis

    Objective To evaluate the clinical efficacy and safety of triple-antiplatelet treatment based on Cilostazol for restenosis after percutaneous coronary intervention. Methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 3, 2009), PubMed (1966 to 2009), EMbase (1974 to 2009), CNKI (1994 to 2009), CBM (1978 to Feb. 2009), VIP (1989 to Feb. 2009), and CMD Digital Periodicals (1998 to 2009). Two reviewers independently evaluated the quality of the included studies and extracted the data. Meta-analyses were performed using RevMan 5.0 software. Results Five randomized controlled trials (RCTs) involving 2 348 patients were included. The results of meta-analyses showed that triple-antiplatelet treatment based on Cilostazol could increase minimum lumen diameter (MD=0.31, 95%CI 0.11 to 0.51) and decrease restenosis rate (OR=0.49, 95%CI 0.37 to 0.65). In addition, it could decrease death rate (OR=0.52, 95%CI 0.31 to 0.88), but it could not change target-vessel revascularization, stroke rate, palpitation rate, and the rate of major adverse cardiac and cerebral events and major adverse cardiac events. Conclusion Evidence shows that triple-antiplatelet treatment based on Cilostazol could increase minimum lumen diameter and decrease restenosis rate and death rate. Their clinical application is worthy to be advocated.

    Release date:2016-09-07 11:23 Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content